Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Delpacibart zotadirsen in Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: NCT06244082 Clinical Landscape Report 2026
18 September 2026
NCT06244082 clinical landscape for Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
BMN-351 in Muscular Dystrophy, Duchenne: NCT06280209 Clinical Landscape Report 2026
18 September 2026
NCT06280209 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bemiltenase alfa in Hemophilia B: NCT06289166 Clinical Landscape Report 2026
18 September 2026
NCT06289166 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant coagulation factor VIII(Chia Tai-Tianqing) in Hemophilia A: NCT06297655 Clinical Landscape Report 2026
18 September 2026
NCT06297655 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Armocibart in Hemophilia B: NCT06312475 Clinical Landscape Report 2026
18 September 2026
NCT06312475 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deramiocel in Cardiomyopathies: NCT06304064 Clinical Landscape Report 2026
18 September 2026
NCT06304064 clinical landscape for Cardiomyopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SPK-8011 in Hemophilia A: NCT06297486 Clinical Landscape Report 2026
18 September 2026
NCT06297486 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hemophilia A: NCT06320626 Clinical Landscape Report 2026
18 September 2026
NCT06320626 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tranexamic Acid in Hemorrhage: NCT06345833 Clinical Landscape Report 2026
18 September 2026
NCT06345833 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SR-604 in Hemophilia B: NCT06349473 Clinical Landscape Report 2026
18 September 2026
NCT06349473 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EN-001 (Encell) in Muscular Dystrophy, Duchenne: NCT06328725 Clinical Landscape Report 2026
18 September 2026
NCT06328725 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LNP-1265/REGV-131 in Hemophilia B: NCT06379789 Clinical Landscape Report 2026
18 September 2026
NCT06379789 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.